METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression

N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and ne...

Full description

Saved in:
Bibliographic Details
Published inExperimental hematology & oncology Vol. 11; no. 1; pp. 14 - 16
Main Authors Guo, Yu-Qing, Wang, Qiang, Wang, Jun-Guo, Gu, Ya-Jun, Song, Pan-Pan, Wang, Shou-Yu, Qian, Xiao-Yun, Gao, Xia
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 14.03.2022
BioMed Central
BMC
Subjects
CDC25B
Cell cycle
Comparative analysis
Development and progression
Health aspects
HNSCC
Immunohistochemistry
m6A
Messenger RNA
Metastasis
Methylation
Methylene blue
Methyltransferases
METTL3
Prognosis
Squamous cell carcinoma
China
m6A
HNSCC
Cell cycle
METTL3
CDC25B
Online AccessGet full text

Cover

Abstract N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC). The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo. M6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression. METTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC.
AbstractList Abstract Background N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC). Methods The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo. Results M6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression. Conclusions METTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC.
Abstract Background N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC). Methods The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo. Results M6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression. Conclusions METTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC.
N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC). The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo. M6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression. METTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC.
N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC).BACKGROUNDN6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC).The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo.METHODSThe prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo.M6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression.RESULTSM6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression.METTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC.CONCLUSIONSMETTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC.
N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC). The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo. M6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression. METTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC.
Background N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC). Methods The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo. Results M6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression. Conclusions METTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC. Keywords: m6A, METTL3, CDC25B, Cell cycle, HNSCC
ArticleNumber 14
Audience Academic
Author Guo, Yu-Qing
Gao, Xia
Wang, Shou-Yu
Qian, Xiao-Yun
Wang, Jun-Guo
Wang, Qiang
Gu, Ya-Jun
Song, Pan-Pan
Author_xml – sequence: 1
  givenname: Yu-Qing
  surname: Guo
  fullname: Guo, Yu-Qing
  organization: Medical School of Nanjing University, Nanjing, 210093, Jiangsu, China
– sequence: 2
  givenname: Qiang
  surname: Wang
  fullname: Wang, Qiang
  organization: Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China
– sequence: 3
  givenname: Jun-Guo
  surname: Wang
  fullname: Wang, Jun-Guo
  organization: Research Institute of Otolaryngology, Nanjing, 210008, China
– sequence: 4
  givenname: Ya-Jun
  surname: Gu
  fullname: Gu, Ya-Jun
  organization: Research Institute of Otolaryngology, Nanjing, 210008, China
– sequence: 5
  givenname: Pan-Pan
  surname: Song
  fullname: Song, Pan-Pan
  organization: Research Institute of Otolaryngology, Nanjing, 210008, China
– sequence: 6
  givenname: Shou-Yu
  surname: Wang
  fullname: Wang, Shou-Yu
  email: sywang@nju.edu.cn, sywang@nju.edu.cn, sywang@nju.edu.cn
  organization: Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, 210093, China. sywang@nju.edu.cn
– sequence: 7
  givenname: Xiao-Yun
  surname: Qian
  fullname: Qian, Xiao-Yun
  email: qxy522@163.com, qxy522@163.com, qxy522@163.com, qxy522@163.com
  organization: Department of Otolaryngology Head and Neck Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, No.321 Zhongshan Road, Nanjing, 210008, Jiangsu, China. qxy522@163.com
– sequence: 8
  givenname: Xia
  orcidid: 0000-0002-4539-5929
  surname: Gao
  fullname: Gao, Xia
  email: gaoxiaent@163.com, gaoxiaent@163.com, gaoxiaent@163.com, gaoxiaent@163.com
  organization: Department of Otolaryngology Head and Neck Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, No.321 Zhongshan Road, Nanjing, 210008, Jiangsu, China. gaoxiaent@163.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35287752$$D View this record in MEDLINE/PubMed
BookMark eNptks1u1DAUhSNUREvpC7BAlpAQmxTbcfyzQRqmBSoNYjOsLcd2Mi6JPbUTJN6-zqRUMxLOws71d07i6_O6OPPB26J4i-A1Qpx-SgQiSkqIcQkhrmlZvSguMKK4rCgSZ0fr8-IqpXuYB8WUI_aqOK9qzBmr8UUx_rjdbjcVGIKZejXaBAa6mt9c67QaXfAgtGB9s8b1F6C8AfsYhjBzO6vMoeKt_g3Sw6SGMCWgbd8DraJ2PgwKDKp3nVd-nIVdtCllyzfFy1b1yV49zZfFr6-32_X3cvPz2916tSl1TelYtoJxogi2lmjBISIaGYQYVxpi24qmgdoYDYVm1KC64dxwgRvGoKkJxUhXl8Xd4muCupf76AYV_8qgnDwUQuykiqPTvZWcWYoaji2sEKkQ5cZizRvBGBNQKJO9Pi9e-6kZrNHWj1H1J6anO97tZBf-SC6QoIRlg49PBjE8TDaNcnBp7pbyNjdOYloJjOv8vYy-X9BO5V9zvg3ZUc-4XFEhaoIEwZm6_g-VH2MHp3NaWpfrJ4IPR4J8f_24S6Gf5ltOpyBeQB1DStG2z8dEUM7pk0v6ZE6fPKRPVln07rhBz5J_WaseAfuA1NQ
CitedBy_id crossref_primary_10_1186_s40164_024_00477_8
crossref_primary_10_1002_kjm2_12626
crossref_primary_10_1186_s40164_022_00298_7
crossref_primary_10_3390_ijms241310733
crossref_primary_10_1096_fj_202301232R
crossref_primary_10_2147_CMAR_S391067
crossref_primary_10_1016_j_lfs_2024_122417
crossref_primary_10_1186_s12964_023_01360_5
crossref_primary_10_1002_cbin_12087
crossref_primary_10_1007_s12672_022_00557_3
crossref_primary_10_1016_j_heliyon_2024_e26262
crossref_primary_10_18632_aging_204371
crossref_primary_10_3390_ijms24021665
Cites_doi 10.1021/acs.analchem.5b03962
10.1038/nrm.2016.132
10.1016/0092-8674(75)90158-0
10.3322/caac.21492
10.1038/nature24678
10.1073/pnas.71.10.3971
10.1186/s13045-020-00927-w
10.1634/theoncologist.2009-0289
10.1111/jop.12381
10.1186/s13045-020-00942-x
10.1016/j.bbrc.2016.11.077
10.3892/or.2014.3061
10.1016/j.gde.2017.10.005
10.1073/pnas.1602883113
10.1016/j.prp.2019.152666
10.1177/1756284819895435
10.1038/nature14281
10.1016/j.canlet.2017.11.018
10.1002/mc.22782
10.5301/JBM.5000030
10.1007/s13277-015-4648-8
10.1093/nar/gkx1030
10.1056/NEJMoa0912217
10.1159/000446117
10.1159/000477127
10.1038/sj.onc.1206926
10.1016/j.ejca.2016.11.018
10.1038/nature11112
10.14740/wjon1104w
10.1083/jcb.200503066
10.1186/s40164-021-00234-1
10.1002/hep.29683
10.1515/CCLM.2011.635
10.1186/s13045-020-00895-1
10.3322/caac.21551
10.1126/science.aad8711
10.1021/jm0102046
10.1038/labinvest.3780254
10.7314/APJCP.2013.14.9.5495
10.1186/1479-5876-8-81
10.1136/gutjnl-2019-319639
10.1038/s41419-018-1224-3
10.3389/fonc.2020.553045
10.1006/excr.2000.4872
10.1016/j.humpath.2007.03.006
10.1038/nrg3724
10.1002/jcb.25967
10.1186/s13045-021-01129-8
10.1158/1535-7163.MCT-06-0099
10.1038/s41580-019-0168-5
10.1038/nrc2169
10.1093/narcan/zcaa039
10.1016/S1470-2045(14)70228-1
10.1016/j.ygyno.2018.09.015
10.1186/s13045-020-00872-8
10.1016/j.bmc.2004.11.039
ContentType Journal Article
Copyright 2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
The Author(s) 2022
Copyright_xml – notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: The Author(s) 2022
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1186/s40164-022-00256-3
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef

PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2162-3619
EndPage 16
ExternalDocumentID oai_doaj_org_article_87e61b82e03143168de2c8b9777909ad
A699541942
10_1186_s40164_022_00256_3
35287752
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Project of Outstanding Youth Training in Health System, Nanjing, China
  grantid: QRX17012
– fundername: Project of Invigorating Health Care through Science, Technology and Education, Nanjing, China
  grantid: ZDXKB2016015
– fundername: ;
  grantid: QRX17012
– fundername: ;
  grantid: ZDXKB2016015
GroupedDBID -A0
0R~
3V.
53G
5VS
7X7
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFS
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AFKRA
AFPKN
AHBYD
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
EBLON
EBS
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
IHW
ITC
KQ8
M48
M~E
NPM
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RBZ
ROL
RPM
RSV
SMD
SOJ
UKHRP
AAYXX
CITATION
AFGXO
ABVAZ
AFNRJ
7X8
5PM
ID FETCH-LOGICAL-c566t-f9784a42ee4c98014c1d1178ac02ef9bb0cddc09c76d15b88d892b770d54621c3
IEDL.DBID RPM
ISSN 2162-3619
IngestDate Tue Oct 22 15:14:15 EDT 2024
Tue Sep 17 20:59:05 EDT 2024
Sat Oct 26 04:42:21 EDT 2024
Fri Feb 23 00:10:14 EST 2024
Tue Nov 12 23:24:54 EST 2024
Tue Aug 20 22:12:49 EDT 2024
Thu Sep 12 19:24:53 EDT 2024
Sat Nov 02 11:58:30 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords m6A
HNSCC
Cell cycle
METTL3
CDC25B
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c566t-f9784a42ee4c98014c1d1178ac02ef9bb0cddc09c76d15b88d892b770d54621c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4539-5929
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919647/
PMID 35287752
PQID 2639225779
PQPubID 23479
PageCount 16
ParticipantIDs doaj_primary_oai_doaj_org_article_87e61b82e03143168de2c8b9777909ad
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8919647
proquest_miscellaneous_2639225779
gale_infotracmisc_A699541942
gale_infotracacademiconefile_A699541942
gale_healthsolutions_A699541942
crossref_primary_10_1186_s40164_022_00256_3
pubmed_primary_35287752
PublicationCentury 2000
PublicationDate 2022-03-14
PublicationDateYYYYMMDD 2022-03-14
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-14
  day: 14
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Experimental hematology & oncology
PublicationTitleAlternate Exp Hematol Oncol
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References I Barbieri (256_CR21) 2017; 552
Y Fu (256_CR48) 2014; 15
A Jou (256_CR8) 2017; 40
SG Cao (256_CR37) 2005; 13
B Gupta (256_CR1) 2016; 91
J Ledermann (256_CR32) 2014; 15
AB Bona (256_CR39) 2020; 13
P Boccaletto (256_CR46) 2018; 46
RL Siegel (256_CR2) 2019; 69
C Puttipanyalears (256_CR41) 2013; 14
HM Guo (256_CR53) 2020; 10
NS Alyasiri (256_CR43) 2013; 28
H Albert (256_CR61) 2011; 49
D Pulte (256_CR7) 2010; 15
T Xia (256_CR52) 2019; 215
MJ Du (256_CR28) 2017; 482
YZ Li (256_CR47) 2018; 34
L Boldrini (256_CR58) 2007; 38
X Cai (256_CR26) 2018; 415
W Huang (256_CR15) 2021; 14
F Bray (256_CR3) 2018; 68
S Zaccara (256_CR14) 2019; 20
HC Chen (256_CR42) 2016; 45
JB Li (256_CR45) 2014; 31
H Qin (256_CR9) 2020; 13
R Desrosiers (256_CR10) 1974; 71
PS Sushma (256_CR44) 2016; 37
AK Dhull (256_CR4) 2018; 9
W Wu (256_CR59) 2003; 63
J Guo (256_CR60) 2004; 23
KK Ang (256_CR6) 2010; 363
MN Chen (256_CR27) 2018; 67
PP Zhang (256_CR29) 2018; 9
CPC De Souza (256_CR33) 2000; 257
WF Hua (256_CR30) 2018; 151
J Huang (256_CR55) 2021; 10
D Jin (256_CR31) 2020; 13
A Lindqvist (256_CR34) 2005; 171
S Hernandez (256_CR57) 2001; 81
J Cairns (256_CR62) 2020; 2
X Deng (256_CR16) 2018; 48
L O'Connor (256_CR22) 2016; 89
J Dong (256_CR56) 2010; 8
BS Zhao (256_CR12) 2017; 18
W Huang (256_CR20) 2016; 88
C Zhang (256_CR51) 2016; 113
D Dominissini (256_CR19) 2012; 485
JS Lazo (256_CR38) 2001; 44
WV Gilbert (256_CR49) 2016; 352
CM Wei (256_CR11) 1975; 4
B Bugler (256_CR35) 2006; 5
R Boutros (256_CR36) 2007; 7
Z Liu (256_CR5) 2017; 72
XX Ma (256_CR54) 2020; 24
Q Wang (256_CR23) 2020; 69
CR Alarcón (256_CR13) 2015; 519
Y Zhao (256_CR18) 2020; 13
L Lili (256_CR40) 2014; 21
Q Wang (256_CR24) 2020; 13
W Wei (256_CR17) 2017; 118
K Taketo (256_CR25) 2018; 52
S Zhou (256_CR50) 2018; 57
References_xml – volume: 88
  start-page: 1378
  issue: 2
  year: 2016
  ident: 256_CR20
  publication-title: Anal Chem
  doi: 10.1021/acs.analchem.5b03962
  contributor:
    fullname: W Huang
– volume: 18
  start-page: 31
  issue: 1
  year: 2017
  ident: 256_CR12
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm.2016.132
  contributor:
    fullname: BS Zhao
– volume: 4
  start-page: 379
  issue: 4
  year: 1975
  ident: 256_CR11
  publication-title: Cell
  doi: 10.1016/0092-8674(75)90158-0
  contributor:
    fullname: CM Wei
– volume: 68
  start-page: 394
  issue: 6
  year: 2018
  ident: 256_CR3
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21492
  contributor:
    fullname: F Bray
– volume: 552
  start-page: 126
  issue: 7683
  year: 2017
  ident: 256_CR21
  publication-title: Nature
  doi: 10.1038/nature24678
  contributor:
    fullname: I Barbieri
– volume: 71
  start-page: 3971
  issue: 10
  year: 1974
  ident: 256_CR10
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.71.10.3971
  contributor:
    fullname: R Desrosiers
– volume: 13
  start-page: 90
  issue: 1
  year: 2020
  ident: 256_CR9
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-020-00927-w
  contributor:
    fullname: H Qin
– volume: 15
  start-page: 994
  issue: 9
  year: 2010
  ident: 256_CR7
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0289
  contributor:
    fullname: D Pulte
– volume: 45
  start-page: 409
  issue: 6
  year: 2016
  ident: 256_CR42
  publication-title: J Oral Pathol Med
  doi: 10.1111/jop.12381
  contributor:
    fullname: HC Chen
– volume: 13
  start-page: 1
  issue: 1
  year: 2020
  ident: 256_CR31
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-020-00942-x
  contributor:
    fullname: D Jin
– volume: 482
  start-page: 582
  issue: 4
  year: 2017
  ident: 256_CR28
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2016.11.077
  contributor:
    fullname: MJ Du
– volume: 31
  start-page: 2206
  issue: 5
  year: 2014
  ident: 256_CR45
  publication-title: Oncol Rep
  doi: 10.3892/or.2014.3061
  contributor:
    fullname: JB Li
– volume: 48
  start-page: 1
  year: 2018
  ident: 256_CR16
  publication-title: Curr Opin Genet Dev
  doi: 10.1016/j.gde.2017.10.005
  contributor:
    fullname: X Deng
– volume: 113
  start-page: E2047
  issue: 14
  year: 2016
  ident: 256_CR51
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1602883113
  contributor:
    fullname: C Zhang
– volume: 215
  start-page: 152666
  issue: 11
  year: 2019
  ident: 256_CR52
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2019.152666
  contributor:
    fullname: T Xia
– volume: 13
  start-page: 1
  year: 2020
  ident: 256_CR39
  publication-title: Ther Adv Gastroenterol
  doi: 10.1177/1756284819895435
  contributor:
    fullname: AB Bona
– volume: 519
  start-page: 4
  issue: 7544
  year: 2015
  ident: 256_CR13
  publication-title: Nature
  doi: 10.1038/nature14281
  contributor:
    fullname: CR Alarcón
– volume: 415
  start-page: 11
  year: 2018
  ident: 256_CR26
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2017.11.018
  contributor:
    fullname: X Cai
– volume: 57
  start-page: 590
  issue: 5
  year: 2018
  ident: 256_CR50
  publication-title: Mol Carcinog
  doi: 10.1002/mc.22782
  contributor:
    fullname: S Zhou
– volume: 28
  start-page: 298
  issue: 3
  year: 2013
  ident: 256_CR43
  publication-title: Int J Biol Markers
  doi: 10.5301/JBM.5000030
  contributor:
    fullname: NS Alyasiri
– volume: 37
  start-page: 7625
  issue: 6
  year: 2016
  ident: 256_CR44
  publication-title: Tumor Biol
  doi: 10.1007/s13277-015-4648-8
  contributor:
    fullname: PS Sushma
– volume: 46
  start-page: D303
  issue: D1
  year: 2018
  ident: 256_CR46
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx1030
  contributor:
    fullname: P Boccaletto
– volume: 363
  start-page: 24
  issue: 1
  year: 2010
  ident: 256_CR6
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0912217
  contributor:
    fullname: KK Ang
– volume: 91
  start-page: 13
  issue: 1
  year: 2016
  ident: 256_CR1
  publication-title: Oncology
  doi: 10.1159/000446117
  contributor:
    fullname: B Gupta
– volume: 40
  start-page: 328
  issue: 6
  year: 2017
  ident: 256_CR8
  publication-title: Oncol Res Treat
  doi: 10.1159/000477127
  contributor:
    fullname: A Jou
– volume: 23
  start-page: 71
  issue: 1
  year: 2004
  ident: 256_CR60
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206926
  contributor:
    fullname: J Guo
– volume: 72
  start-page: 166
  year: 2017
  ident: 256_CR5
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2016.11.018
  contributor:
    fullname: Z Liu
– volume: 485
  start-page: 201
  issue: 7397
  year: 2012
  ident: 256_CR19
  publication-title: Nature
  doi: 10.1038/nature11112
  contributor:
    fullname: D Dominissini
– volume: 9
  start-page: 80
  issue: 3
  year: 2018
  ident: 256_CR4
  publication-title: World J Oncol
  doi: 10.14740/wjon1104w
  contributor:
    fullname: AK Dhull
– volume: 171
  start-page: 35
  issue: 1
  year: 2005
  ident: 256_CR34
  publication-title: J Cell Biol
  doi: 10.1083/jcb.200503066
  contributor:
    fullname: A Lindqvist
– volume: 10
  start-page: 40
  issue: 1
  year: 2021
  ident: 256_CR55
  publication-title: Exp Hematol Oncol
  doi: 10.1186/s40164-021-00234-1
  contributor:
    fullname: J Huang
– volume: 67
  start-page: 2254
  issue: 6
  year: 2018
  ident: 256_CR27
  publication-title: Hepatology
  doi: 10.1002/hep.29683
  contributor:
    fullname: MN Chen
– volume: 52
  start-page: 621
  issue: 2
  year: 2018
  ident: 256_CR25
  publication-title: Int J Oncol
  contributor:
    fullname: K Taketo
– volume: 49
  start-page: 1707
  issue: 10
  year: 2011
  ident: 256_CR61
  publication-title: Clin Chem Lab Med
  doi: 10.1515/CCLM.2011.635
  contributor:
    fullname: H Albert
– volume: 13
  start-page: 1
  issue: 1
  year: 2020
  ident: 256_CR24
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-020-00895-1
  contributor:
    fullname: Q Wang
– volume: 69
  start-page: 7
  issue: 1
  year: 2019
  ident: 256_CR2
  publication-title: Ca-a Cancer J Clin
  doi: 10.3322/caac.21551
  contributor:
    fullname: RL Siegel
– volume: 34
  start-page: 9
  issue: 7
  year: 2018
  ident: 256_CR47
  publication-title: Chinese J Biochem Mol Biol
  contributor:
    fullname: YZ Li
– volume: 352
  start-page: 1408
  issue: 6292
  year: 2016
  ident: 256_CR49
  publication-title: Science
  doi: 10.1126/science.aad8711
  contributor:
    fullname: WV Gilbert
– volume: 63
  start-page: 6195
  issue: 19
  year: 2003
  ident: 256_CR59
  publication-title: Cancer Res
  contributor:
    fullname: W Wu
– volume: 44
  start-page: 4042
  issue: 24
  year: 2001
  ident: 256_CR38
  publication-title: J Med Chem
  doi: 10.1021/jm0102046
  contributor:
    fullname: JS Lazo
– volume: 81
  start-page: 465
  issue: 4
  year: 2001
  ident: 256_CR57
  publication-title: Lab Invest
  doi: 10.1038/labinvest.3780254
  contributor:
    fullname: S Hernandez
– volume: 14
  start-page: 5495
  issue: 9
  year: 2013
  ident: 256_CR41
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/APJCP.2013.14.9.5495
  contributor:
    fullname: C Puttipanyalears
– volume: 8
  start-page: 81
  year: 2010
  ident: 256_CR56
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-8-81
  contributor:
    fullname: J Dong
– volume: 69
  start-page: 1193
  issue: 7
  year: 2020
  ident: 256_CR23
  publication-title: Gut
  doi: 10.1136/gutjnl-2019-319639
  contributor:
    fullname: Q Wang
– volume: 9
  start-page: 1
  year: 2018
  ident: 256_CR29
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-018-1224-3
  contributor:
    fullname: PP Zhang
– volume: 10
  start-page: 1842
  year: 2020
  ident: 256_CR53
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.553045
  contributor:
    fullname: HM Guo
– volume: 257
  start-page: 11
  issue: 1
  year: 2000
  ident: 256_CR33
  publication-title: Exp Cell Res
  doi: 10.1006/excr.2000.4872
  contributor:
    fullname: CPC De Souza
– volume: 38
  start-page: 1563
  issue: 10
  year: 2007
  ident: 256_CR58
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2007.03.006
  contributor:
    fullname: L Boldrini
– volume: 15
  start-page: 293
  issue: 5
  year: 2014
  ident: 256_CR48
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg3724
  contributor:
    fullname: Y Fu
– volume: 21
  start-page: 7
  issue: 6
  year: 2014
  ident: 256_CR40
  publication-title: Chin J Cancer Biother
  contributor:
    fullname: L Lili
– volume: 118
  start-page: 2534
  issue: 9
  year: 2017
  ident: 256_CR17
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.25967
  contributor:
    fullname: W Wei
– volume: 14
  start-page: 1
  issue: 1
  year: 2021
  ident: 256_CR15
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01129-8
  contributor:
    fullname: W Huang
– volume: 5
  start-page: 1446
  issue: 6
  year: 2006
  ident: 256_CR35
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-06-0099
  contributor:
    fullname: B Bugler
– volume: 20
  start-page: 608
  issue: 10
  year: 2019
  ident: 256_CR14
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-019-0168-5
  contributor:
    fullname: S Zaccara
– volume: 89
  start-page: 513
  issue: 4
  year: 2016
  ident: 256_CR22
  publication-title: Yale J Biol Med
  contributor:
    fullname: L O'Connor
– volume: 7
  start-page: 495
  issue: 7
  year: 2007
  ident: 256_CR36
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2169
  contributor:
    fullname: R Boutros
– volume: 2
  start-page: zcaa039
  issue: 4
  year: 2020
  ident: 256_CR62
  publication-title: NAR Cancer
  doi: 10.1093/narcan/zcaa039
  contributor:
    fullname: J Cairns
– volume: 15
  start-page: 852
  issue: 8
  year: 2014
  ident: 256_CR32
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70228-1
  contributor:
    fullname: J Ledermann
– volume: 24
  start-page: 3565
  issue: 7
  year: 2020
  ident: 256_CR54
  publication-title: Eur Rev Med Pharmacol Sci
  contributor:
    fullname: XX Ma
– volume: 151
  start-page: 356
  issue: 2
  year: 2018
  ident: 256_CR30
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2018.09.015
  contributor:
    fullname: WF Hua
– volume: 13
  start-page: 35
  issue: 1
  year: 2020
  ident: 256_CR18
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-020-00872-8
  contributor:
    fullname: Y Zhao
– volume: 13
  start-page: 999
  issue: 4
  year: 2005
  ident: 256_CR37
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmc.2004.11.039
  contributor:
    fullname: SG Cao
SSID ssj0000626817
Score 2.3695118
Snippet N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA...
Abstract Background N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by...
Background N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by...
Abstract Background N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 14
SubjectTerms CDC25B
Cell cycle
Comparative analysis
Development and progression
Health aspects
HNSCC
Immunohistochemistry
m6A
Messenger RNA
Metastasis
Methylation
Methylene blue
Methyltransferases
METTL3
Prognosis
Squamous cell carcinoma
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELZQD4gLojzTFjASEgdkdf1YP45paFUhwimVerP8CiCUTSHp_2fGu4my4sCF49qz0trztHfmG0Leg4cLEuw-E9K0TAnjWAw8sTZZZ4tWkdeisPlXfX2jPt-2twetvjAnrIcH7jfu3JqiebSiIM46dlnKRSQbIWwxrnEhV-vbuIPDVG-Dhbbc7KpkrD7fKASTYpi8Xv08kyNPVAH7_zbLB35pnDN54ISunpDHQ_RIp_1XH5MHpXtKHs6H_-PPyHZ-uVh8kXS1ztiWq2zoSk_xCROCKg_oeklnn2aivaChy_SuZuMBHdjkXEe6kn7Sza_7gHcCFO_1acJ-Q916FegKovZvmDpDa15Xj-nxnNxcXS5m12zoq8ASBG9btoSTowpKlKKSQ_SYxDPnxobUiLJ0MTYp59S4ZHTmbbQ2WyeiMU1ulRY8yRfkqFt35RWhiofctjCJsPku6ggBgDRZSh24XkY9IR93e-zvevgMX48dVvueIx444itHvJyQC2TDnhKhr-sACIQfBML_SyAm5C0y0fd1pHsF9lON0HfcKTEhHyoFqjDwMoWhEgGWhGBYI8qzESWoXhpNv9sJiscpzFfrCnDHCwj8wFLCJ03Iy15w9qtCPB1jWnjbjERqtOzxTPfje0X-tg7x08zJ_9inU_JIVG2QjKszcrT9fV9eQ4C1jW-qLv0BXTkesA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Jb9NAFB6VIiEuiJ1AgUFC4oAMmcWzHBBKQ6sKEU6J1NtotrQI4rRJKsG_572xE9WiB472PC_jt4_ffI-Qt-DhvAC7X3Gh60pybavgWazqaKzJSgZWNoVNvquTmfx6Wp_ukW27o-4Drm9M7bCf1Gz168Pvyz-fQeE_FYU36uNaIk5UhXXpxYVX4ha5zSVk6ljK14X7rWXmypQmvJwpXglIHrb7aG68Tc9XFUj_fw33Nc_Vr6q85qaO75N7XXxJR61APCB7uXlI7ky6P-iPyGZyNJ1-E3SxTNi4K6_pQo3wCEuGCpfock7HX8a8PqS-SfSi1OsBHVjtVM40Of6k68srj6sGFFf-acSORM1y4ekC4vozLK6hpfKrRf14TGbHR9PxSdV1XqgihHebag65pfSS5yyjRXyZyBJj2vg45HluQxjGlOLQRq0Sq4MxyVgetB6mWirOonhC9ptlk58RKplPdQ2DCKxvgwoQIgidhFCeqXlQA_J--43dRQuw4UpiYpRrOeKAI65wxIkBOUQ27CgRHLucWK7OXKdrzuisWDA8IzQ_NuZKmUcTINLVdmh9GpDXyETX7jTdqbgbKQTHY1byAXlXKFDsgJfRd3sVYEoIl9WjPOhRgnLG3vCbraA4HMKKtiYDdxyH0BBsKbzSgDxtBWc3K0Tc0bqGq3VPpHrT7o80P84LNrixiLCmn__Hc1-Qu7wIu6iYPCD7m9VVfgkR1ia8KmrzF_MGHiI
  priority: 102
  providerName: Scholars Portal
Title METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression
URI https://www.ncbi.nlm.nih.gov/pubmed/35287752
https://www.proquest.com/docview/2639225779
https://pubmed.ncbi.nlm.nih.gov/PMC8919647
https://doaj.org/article/87e61b82e03143168de2c8b9777909ad
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe2ISFeEN8ERjESEg8oa-04tvPYlk5TRacJOqlvVvzRbYKkZe3-f-6cpmrEGy-NGl-kuPfhs_u73xHyGVa4MoO4n_JM5angqkhtyVyaO13oIIVlsShsdikvrsV0kS-OSN7WwkTQvrN3Z_Xv6qy-u43YynXl-i1OrH81G-sCaaRU_5gcg4EebNGb8MulZqotkNGyvxHII5Uibj0u8Sk2z0FWE6Vy3lmPIm3_v8H5YHXqIicPlqLzZ-TpLoekw-Zdn5OjUL8gj2e7f8lfku1sMp9_z2i18ticK2xoJYf4DWFBURN0taTjb2Oej2hZe7qOmDyQg8js4506uF908-ehxJMBiqf71GHXoXpVlbSC3P0GATQ0orsaZo9X5Pp8Mh9fpLvuCqmDFG6bLmH_KErBQxCuQA4ZxzxjSpduwMOysHbgvHeDwinpWW619rrgVqmBz4XkzGWvyUm9qsNbQgUrfZ7DIJLnF1ZaSAMy5bNMlkwurUzI1_Y3NuuGRMPEzYeWplGOAeWYqByTJWSEathLIgF2vLG6vzE7MzBaBcms5gHp97H5lg_caQvZrCoGRekT8hGVaJpq0r0bm6FEAjxWCJ6QL1ECHRl06cpdPQJMCSmxOpKnHUlwQNcZ_tQaisEhRK3VAbRjOKR_EC_hlRLypjGc_axa-0uI6phUZ9rdEXCHyP-9M_93__3ke_KER2_IUiZOycn2_iF8gNxqa3vgUQvVI4-Gw-nPKVxHk8urH714UgGfM6F70dv-Am8uJgI
link.rule.ids 230,315,730,783,787,867,888,2109,2228,24330,27936,27937,31732,33757,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGkIAXxJ3AYEZC4gFljR3Hl8eubCrQTjx00t4s3zomSFrW7v_j4yRVI954THwixT1Xp9_5DkIfY4YzZYz7OS1FlTMqVG4NcXnlpJKBM0tSU9j8gk8v2ber6uoAVX0vTALtO3tz0vyuT5qbnwlbua7dqMeJjX7MJ1IBjZQY3UP3o78WbO-Q3gZgyiURfYuM5KMNAyapHJDrKcnnMD4HeE2EqOggIyXi_n_D815-GmIn95LR-RP0uKsi8bh926foIDTP0IN59z_5c7Sdny0WsxLXKw_jucIG13wMVwAMSrrAqyWefJnQ6hSbxuN1QuVFuRibfbrTBPcLb_7cGfg2gOH7PnYwd6hZ1QbXsXq_BggNTviultvjBbo8P1tMpnk3XyF3sYjb5st4gmSG0RCYU8Ai44gnREjjChqWytrCee8K5QT3pLJSeqmoFaLwFeOUuPIlOmxWTXiNMCPGV1VcBPp8ZbmNhUApfFlyQ_jS8gx97n9jvW5pNHQ6fkiuW-XoqBydlKPLDJ2CGnaSQIGdbqxur3VnCFqKwImVNAABP4zf8oE6aWM9K1ShjM_QMShRt_2kO0fWYw4UeEQxmqFPSQJcOerSma4jIW4JSLEGkkcDyeiCbrD8oTcUDUuAW2tC1I6msQCMETO-UoZetYaz21VvfxkSA5MabHu4Eh0iMYB3DvDmv588Rg-ni_lMz75efH-LHtHkGWVO2BE63N7ehXex0tra98mv_gITgCN8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgSBMviDuBwYyExAPKGjuOL49dt2rAOu2hk_Zm-ZZtgqRl7f4_Pk5aNeKNx8QnUpxztfP5Owh9iRnOlDHu57QUVc6oULk1xOWVk0oGzixJh8JmF_zsiv24rq53Wn0l0L6zd0ft7-aovbtN2Mpl40YbnNjocjaRCmikxGjp69Fj9CT6bMF3FupdEKZcErE5JiP5aMWATSoH9HpK9Dm00AFuEyEqOshKibz_3xC9k6OG-MmdhDR9jp71lSQed2_8Aj0K7Uu0P-v_lb9C69npfH5e4mbhoUVXWOGGj-EKwEFJH3hR48nJhFbH2LQeLxMyL8rF-OzTnTa4X3j158HA_gCGPX7soPdQu2gMbmIFfwMwGpwwXh2_x2t0NT2dT87yvsdC7mIht87ruIpkhtEQmFPAJOOIJ0RI4woaamVt4bx3hXKCe1JZKb1U1ApR-IpxSlz5Bu21iza8Q5gR46sqDgKFvrLcxmKgFL4suSG8tjxD3zbfWC87Kg2dliCS6045OipHJ-XoMkPHoIatJNBgpxuL-xvdG4OWInBiJQ1Awg8tuHygTtpY0wpVKOMzdAhK1N2Z0q0z6zEHGjyiGM3Q1yQB7hx16Ux_KiFOCYixBpIHA8nohm4w_HljKBqGALvWhqgdTWMRGKNmfKUMve0MZzurjf1lSAxMajDt4Uh0isQC3jvB-_9-8hDtX55M9fn3i58f0FOaHKPMCTtAe-v7h_AxFltr-ym51V9EvSSP
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=METTL3+modulates+m6A+modification+of+CDC25B+and+promotes+head+and+neck+squamous+cell+carcinoma+malignant+progression&rft.jtitle=Experimental+hematology+%26+oncology&rft.au=Guo%2C+Yu-Qing&rft.au=Wang%2C+Qiang&rft.au=Wang%2C+Jun-Guo&rft.au=Gu%2C+Ya-Jun&rft.date=2022-03-14&rft.issn=2162-3619&rft.eissn=2162-3619&rft.volume=11&rft.issue=1&rft.spage=14&rft_id=info:doi/10.1186%2Fs40164-022-00256-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-3619&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-3619&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-3619&client=summon